News | 18 March 2026
Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
The trial will enroll up to 42 patients in Finland across four cohorts
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Subscribe To Our Newsletter & Stay Updated
